A drug once believed to improve mortality rates of patients with severe sepsis has been withdrawn from the market because new evidence has revealed it fails to do so—10 years after the drug was approved by the US Food and Drug Administration (FDA). Eli Lilly and Company announced on October 25 that it was withdrawing drotrecogin alfa (activated) [Xigris, a recombinant human activated protein C (rhAPC)].
A medication thought to improve mortality rates of patients with severe sepsis has been removed from the market because a recent study found it fared no better than placebo.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Graphic Jump Location
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 13
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.